MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 125
- Registration Number
- NCT01190436
- Locations
- 🇵🇭
Research Site, Manila, Philippines
Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®
Phase 4
Completed
- Conditions
- Dwarfism, Pituitary
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 214
- Registration Number
- NCT01187550
Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
Phase 3
Completed
- Conditions
- Polycystic Ovarian Syndrome
- Interventions
- Drug: Recombinant Human Choriogonadotropin (r-hCG)Drug: Recombinant human follicle stimulating hormone (r-hFSH)
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 136
- Registration Number
- NCT01185704
- Locations
- 🇫🇷
Research Site, Toulouse, France
SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women
Phase 3
Completed
- Conditions
- Ovulation InductionInfertility
- Interventions
- Drug: Gonalef® (Follitropin alfa)Drug: Purified pituitary gonadotropin (Fertinorm-P®)
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 300
- Registration Number
- NCT01185782
- Locations
- 🇯🇵
The University of Tokyo Hospital, Tokyo, Japan
A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization
Phase 4
Withdrawn
- Conditions
- Angina Pectoris
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Registration Number
- NCT01185015
Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization
Phase 3
Completed
- Conditions
- Ovulation InductionIn-Vitro FertilizationInfertility
- Interventions
- Drug: GONAL-f®
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 215
- Registration Number
- NCT01183143
- Locations
- 🇩🇪
Please Contact the Merck KGaA Communication Center, Darmstadt, Germany
A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck
Phase 3
Completed
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 73
- Registration Number
- NCT01177956
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳Fuijan Provincial Tumor Hospital, Fuijian, China
🇨🇳Sun Yat-Sen Univesity Cancer Center, Guangzhou, China
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
Phase 4
Completed
- Conditions
- Growth Hormone DeficiencyDwarfism
- Interventions
- Drug: r-hGH
- First Posted Date
- 2010-07-07
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 34
- Registration Number
- NCT01157793
Colposeptine for the Treatment of Bacterial Vaginosis
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 133
- Registration Number
- NCT01153958
- Locations
- 🇨🇳
Second Hospital of West China Medical School, Sichuan University, Chengdu, China
🇨🇳Obstetrics & Gynaecology Hospital of Fudan University, Shanghai, China
🇨🇳Peking University Shenzhen Hospital, Shenzhen, China
An Observational Study to Evaluate Efficacy, Safety and Clinical Outcomes of Currently Used Pharmaceutical Therapies for Controlled Ovarian Stimulation in Assisted Reproductive Techniques
Completed
- Conditions
- Infertility
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 10103
- Registration Number
- NCT01149070
- Locations
- 🇭🇺
Kaáli Institute, Budapest, Istenhegyi út 54/A, Hungary
© Copyright 2025. All Rights Reserved by MedPath